CD38 and acute myeloid leukemia: The clinical relevance of LSCs is underlined by studies that showed an increased chance of relapse and worse overall survival in AML patients with a high CD34+/CD38- LSC frequency at diagnosis and after induction therapy compared to patients with a low LSC frequency[20].